Live Analyst Rating Changes 1505 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Jessica Tassan
PIPR
Jessica Tassan
Piper Sandler
Wall Street Analyst
★★★★☆
#372
on 13Foresight · ranked by our own returns
72%
Success Rate
+10.2%
Average Return
13 of 18 calls profitable · +1.3% vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 72% of Jessica Tassan's ratings turned a profit when each position was held for 1 year — averaging +10.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

39 Buy 10 Hold 0 Sell
Jessica's Stock Coverage 17 ratings · 2026-06-18
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
CTEV
Claritev
 Jun 03, 2026 BUY Strong Buy
-2.7% avg upside
8 analysts
$61.00
104.98% Upside
 +13.2%
PHR
Phreesia
 May 28, 2026 HOLD Strong Buy
+82.5% avg upside
21 analysts
$12.00
28.29% Upside
 ·
DOCS
Doximity
 May 14, 2026 BUY Buy
+61.4% avg upside
27 analysts
$42.00
105.48% Upside
 +14.8%
HUM
Humana
 May 13, 2026 HOLD Buy
-11.8% avg upside
34 analysts
$254.00
29.78% Downside
 +18.8%
HCAT
Health Catalyst
 May 12, 2026 HOLD Buy
+210.7% avg upside
15 analysts
$2.00
12.95% Upside
 -19.6%
PRVA
Privia Health Group
 May 08, 2026 BUY Strong Buy
+35.2% avg upside
26 analysts
$36.00
53.75% Upside
 -6.2%
HNGE
Hinge Health, Inc. Class A
 May 06, 2026 BUY Strong Buy
+10.5% avg upside
17 analysts
$95.00
41.63% Upside
 +19.1%
UNH
UnitedHealth
 Apr 22, 2026 BUY Strong Buy
+2.5% avg upside
35 analysts
$420.00
5.11% Upside
 +16.0%
CVS
CVS Health
 Mar 31, 2026 BUY Strong Buy
+2.5% avg upside
38 analysts
$99.00
0.09% Downside
 +41.5%
CI
Cigna
 Mar 03, 2026 BUY Strong Buy
+21.9% avg upside
29 analysts
$370.00
29.77% Upside
 +2.0%
ALHC
Alignment Healthcare
 Mar 02, 2026 BUY Strong Buy
+3.0% avg upside
19 analysts
$30.00
40.10% Upside
 +0.0%
TDOC
Teladoc
 Feb 26, 2026 BUY Buy
+278.2% avg upside
37 analysts
$9.00
18.51% Upside
 +32.5%
OMCL
Omnicell
 Feb 23, 2026 BUY Strong Buy
+38.2% avg upside
12 analysts
$49.00
27.27% Upside
 +9.0%
OSCR
Oscar Health
 Nov 26, 2025 BUY Buy
-33.7% avg upside
15 analysts
$25.00
11.49% Downside
 +55.6%
EVH
Evolent Health
 Sep 05, 2025 BUY Strong Buy
+115.8% avg upside
19 analysts
$18.00
285.37% Upside
 -56.1%
AMWL
American Well
 May 23, 2025 HOLD Hold
+61.9% avg upside
15 analysts
$8.00
5.93% Downside
 +1.2%
MDRX
Veradigm
 Jan 17, 2024 HOLD Buy
+207.0% avg upside
22 analysts
$10.00
108.30% Upside
 +2.1%
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Jessica Tassan — Frequently Asked Questions
How accurate are Jessica Tassan's stock ratings?
Based on the calls 13Foresight could measure, about 72% of Jessica's ratings were profitable over a one-year hold, with an average return of +10.2% per rating, or +1.3% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Jessica ranked on 13Foresight?
Jessica Tassan is currently ranked #372 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Jessica cover?
Jessica most recently has ratings on CTEV, PHR, DOCS, HUM, HCAT, PRVA, HNGE, UNH, CVS, CI, ALHC, TDOC and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.